The prevalent with the t(4;11)(q21;q23), but cases of ANLL have also been described with this translocation. Further the t(11;19)(q23;pll) is seen in early B-ALL, common-ALL (c-ALL), ANLL, and occasionally in T-ALL. Other translocations, such as t(10;11)(p11-15;q23) and t(11;17)(q23;q21), are found in ANLL tumors that are otherwise indistinguishable from those discussed above.
11q23 abnormalies miht cause a_tachment of Ser/Pro-rich segments to the NH2 termius of MLL, laddng the zinc-finger region, and that tfranocations occur in early hematopoletic cels, before commitment to distnct linages.
Specific chromosomal translocations in acute leukemias suggest that a variety of oncogenes are activated by them, which lead to cancer. DNA cloning of translocation breakpoints from many acute lymphoblastic leukemias [ALLs; (B-cell or T-cell ALL) (B-ALL or T-ALL)] in humans (1) has revealed several different genes, and animal-model systems have confirmed that some ofthe identified genes can participate in tumorigenesis (2) (3) (4) (5) (6) (7) . Most of these genes seem able to elicit only tumors of a particular hematopoietic lineage, as for example RBTN2/Ttg-2 (8) (9) (10) (11) (12) (13) or TALI/SCL (14) (15) (16) , which are only found in childhood T-ALL. This fact suggests that one effect of translocations in acute leukemia is to activate cellular genes that participate in determination of tumor lineage.
A different situation seems to pertain to the translocations involving the long arm of chromosome 11, band q23, which is prone to translocation with a variety of different chromosomes. Unusually tumors of lymphoid and nonlymphoid lineages have been described, with some correlation of translocation to lineage (17) . For example, t(9;11)(p22;q23) mainly occurs in acute nonlymphoid leukemia (ANLL) but does occur in early B-ALL. The latter phenotype is more
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. prevalent with the t(4;11)(q21;q23), but cases of ANLL have also been described with this translocation. Further the t(11;19)(q23;pll) is seen in early B-ALL, common-ALL (c-ALL), ANLL, and occasionally in T-ALL. Other translocations, such as t(10;11)(p11-15;q23) and t(11;17)(q23;q21), are found in ANLL tumors that are otherwise indistinguishable from those discussed above.
Recently, a gene on chromosome 11q23 designated MLL (also ALL-1 and HRX) (18) (19) (20) (21) (22) (23) has been described that is rearranged in t(4;11) and t(11;19) (18) (19) (20) (21) (22) (24) (25) (26) (27) . These translocations have been studied at the molecular level (18, 19, 21) , and the breakpoints create a fusion of the MLL gene with a gene called AF4 in the case of the t(4;11) (19) restriction enzyme, and the digestion products were separated on 0.8% agarose gels. The gels were blotted (28) onto nylon membranes and hybridized as described (28) with either the myeloid-lymphoid leukemia (MLL) genomic probe P4 (27) [containing exon 8, a 5' MLL probe (EX5/GEB13) which was prepared by reverse transcriptase (RT)-PCR from RS411 cDNA extending from residues 3869 to 4443 of the published MLL sequence (19, 21] , or a 3' MLL probe (VAR8F/EX11B), which was also prepared by RT-PCR from RS411 cDNA, extending from residues 4318 to the BamHI site, in exon 11, at residue 4609 of the published MLL sequence.
Abbreviations: ALL, acute lymphoblastic leukemia; T-ALL, T-cell ALL; B-ALL, B-cell ALL; ANLL, acute nonlymphoid leukemia; RAP, reverse-anchored PCR method; MLL, myeloid-lymphoid leukemia; RT, reverse transcriptase. **To whom reprint requests should be addressed. (these were kept to prepare DNA for genomic analysis), and RNA was prepared from the cytoplasmic fraction by adding SDS to 1.5% and phenol-chloroform extraction. The RNAcontaining aqueous phase was concentrated by ethanol precipitation.
cDNA copies were prepared with total RNA using the primer N6CAS [5'-GATGCGGCCGCCTCGAGCTCANN-NNN-3' (N = A, G, C, orT)] for reverse transcription at 42°C for 60 min with 3 juM primer and total RNA at 250 ,ug/ml in standard buffer (29) . The N6CAS primer was used in preference to oligo(dT) priming because in some cases the RNA quality was low and the utilization of the randomizing primer facilitated heterogeneous priming sites along the length of the mRNA and also tagged each cDNA molecule with a specific priming site (complementary to primer CAS, 5'-GATGCG-GCCGCCTCGAGCTCA-3') for subsequent PCR amplification. Amplification across the t(4;11) junction was done with PCR reactions (30) using EX5UNP (5'-CCTGAATCCAAA-CAGGCCACCACT-3', starting at position 3841 in the previous sequence) (21) plus AF4B1 (5'-GATGAGCTCACT-GAGCTGAAGGTCGTCTTC-3', corresponding to residues 229-251 in Fig. 3 and incorporating a Sac I restriction site for cloning). Amplifications were done with the "touch down" method (31) by using the program 95°C for 1.5 min, reduction from 63°C to 56°C by 20 steps (1.5 min and two cycles at each temperature), 55°C for 1.5 min (14 cycles), and 72°C to a total of 30 cycles (2.5 min). A second round of 30-cycle PCR was done as above with EX5NP [5'-GATAAGCTTCCAG-GAAGTCAAGCAAGCAGG-3', starting at position 3869 in the previous sequence (19, 21) and incorporating a HindIII restriction site for cloning] plus AF4B1. Amplification across the t(11;19) junction was done with PCR reactions using EX5UNP plus ENLB2 [5'-GATGGATCCACGAAGTGC-TGGATGTCACAT-3', corresponding to residues 182-205 in the previous sequence (21) and incorporating a BamHI restriction site for cloning]. Amplifications were done with the touch-down program. A second round of 30-cycle PCR was done with EX5NP plus ENLB2. The PCR products of the t(4;11) or t(11;19) junctions were cleaved with HindIll (EX5NP) and Sac I (AF4B1) orBamHl (ENLB2) and cloned into Phagescript (Stratagene); the sequence of the junctions was obtained with MLL exon 5 (5'-CTCCTAGTGAGC-CCAAG-3'), exon 5-6 (5'-CAGAATCAGGTCCAGAG-3'), exon 7 (5'-CAGATGGAGTCCACAGG-3'), or exon 8 (5'-TGGGAGGCTTAGGAATC-3') primers.
Reverse-Anchored PCR (RAP) to Sequence der(ll) Fusion Transcripts. To clone and sequence the der(11) fusion product, which consists of 5' MLL and 3' unknown sequences, cDNA, prepared with the N6CAS primer (see above), was used for PCR amplification reaction with CAS plus EX5NP primers for 30 cycles as above. This PCR product mixture was subjected to a further 30 PCR cycles with CAS primer plus either primer EX5NP (exon 5) or primer VAR7F (located at the end of exon 7, sequence 5'-GATAAGCTTCAGGAT-CAGAGTGGACTTTAAG-3') or primer VAR8F (located at the end of exon 8, sequence 5'-GATAAGCTTGCCAG-TAGTGGGCATGTAGAG-3'), depending on the position of the breakpoint within MLL (determined by filter-hybridization data) and all having HindIII restriction sites to allow cloning of the PCR products. After the second round of amplification, the PCR reaction was passed through a G50 spin column, size-fractionated on agarose, digested with HindIlI (primers EXSNP, VAR7F, and VAR8F) and Not I (primer CAS), cloned into Phagescript, and sequenced with an appropriate primer (see above). The AF4 sequence was extended by RAP using the published AF4 sequence (19) to design primers. The first round of PCR amplification used primer AF4UNP (5'-CCTACTCCAATGAAGTCCAT-TGTG-3', starting at position 2 in Fig. 3 ) and primer CAS; the second 30 cycles used primer AF4NP (5'-GATAAGCTT-TGACAGCAATACATACGCCTAG-3', starting at position 67 in Fig. 3 and incorporating a HindIII restriction site for cloning) and primer CAS. The final PCR reaction was cleaved with HindIII (primer AF4NP) and Not I (primer CAS) and cloned into Phagescript. AF4-specific clones were detected by using the PCR product of primer AF4FP1 (5'-AAGTT-TCCTTTCCCTACAAAGGAC-3', starting at position 108 in Fig. 2 ) and primer AF4B1, and sequence data were obtained with the primers AF4SP1 (5'-GAACGTCATCCATGCTC-3' starting at position 212 in Fig. 2 ) and AF4SP2 (5'-CGATCAGCACATTCCAG-3', starting at position 343 in Fig. 2 ). Double-stranded sequence was obtained by isolation of inserts from relevant clones and recloning in the appropriate M13. AFX1 clones were obtained by RAP with cDNA made from K45 (32) using the MLL exon 8 primer together with the CAS primer. The chromosome X origin of the derived cDNA sequence was confirmed with use of somatic cell hybrids carrying only human chromosome X on a rodent background (data not shown).
RESULTS
Rearrangements of MLL in Acute Leukemias. Although the MLL gene rearrangement has been shown in t(4;11) and t(11;19) (18) (19) (20) (21) (22) (24) (25) (26) (27) , there is no information on other forms of 11q23 abnormality. A range of tumors with 11q23 translocations were available, and these were analyzed for DNA rearrangement by using a probe (P4) containing exon 8 (27) of MLL (Fig. 1B) . Representative MLL rearrangements in DNA prepared from tumor material, biopsied from acute leukemia patients with 11q23 translocations, are shown in Fig. 1A . All show rearranged bands when the DNA was digested with BamHI, which encompasses exons 5-11 of MLL (18, 19, 21) just upstream of the zinc fingers of MLL (19, 21) .
A summary of rearrangement positions for the various translocations [determined with different enzymes and additional 5' (EX5/GEB13) and 3' (VAR8F/EX11B) MLL probes, see Materials and Methods] is given in Fig. 1C , which shows the position of each rearrangement-e.g., t(1;11) sample 3 has a rearrangement within the Bgl II-EcoRI band. The majority of samples showed rearranged DNA bands when digested with BamHI, although a few samples only showed rearrangements with HindIII, which places the rearrangement position upstream ofMLL exon 5. We assume that these rearrangements represent the translocations (confirmed by sequencing the fusion mRNA junction in some cases); therefore, breakage within MLL appears to occur in the restricted region irrespective of translocation or tumor phenotype.
Deletion (19, 21) , PCR primers were designed that allowed amplification, cloning, and sequence analysis of the fusion mRNA. The AF4 mRNA fusion consistently occurs in one of three places (Table 1) 
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Pre-pre-ALL 6 b Patient number and disease diagnosis are shown with RT-PCR sequence or filter hybridization data [using P4, 5' (EX5/GEB13) or 3' (VAR8F/EX11B) MLL probes; see Fig. 1 ]. Only restriction enzyme data are given for those t(4;11) samples for which sequence data are unavailable (except in those cases where a deletion is also detected), and only BamHI data are indicated. Breakpoint junctions of MLL are indicated by numbers corresponding to known exons, and breakpointjunctions ofAF4 are indicated by letters presumed to be exon boundaries. G, unrearranged; R, rearranged; nd, not determined by RT-PCR sequence. *Adult leukemia.
an extra CAG codon that appears between MLL and the previously reported AF4 break (position b) in a t(4;11) sample (19) , suggesting a minor variation in splice junction. Sample 411-2 breaks at an unusual AF4 position, and this could be an aberrant splice to within an AF4 exon; the reading frame of the fusion protein is nonetheless maintained.
The ENL breakpoint position is completely conserved in all tumors analyzed (designated position b, see Table 2 ) and is identical with that reported (21). Indeed, in three different lineage tumors, the MLL exon 7 is joined to ENL position b. The cumulative data in Table 2 show fusion of exons 6, 7, and 8 of MLL with position b of ENL, even though ENL is associated with several phenotypes at diagnosis.
The AFXI Gene Encodes a Serine-Prolne-Rich Sequence. The complete mRNA sequence of the chromosome 19 fusion partner ENL has been reported (21) , showing a sequence rich in serine and proline codons. To investigate the possible generality of this finding, partial sequence from the fusion mRNA of MLL and AFXI resulting from t(X;11)(ql3;q23) and a partial extension of the sequence of AF4 (19) were obtained. A 3'-RAP was designed (see Materials and Methods) to allow the der(ll) transcripts to be amplified and sequenced [the der(ll) was the primary target because current evidence suggests that this is crucial to tumor occurrence T-ALL 7 b Only restriction enzyme data are given for those t(11;19) samples for which sequence data are unavailable (except in those cases where a deletion is also detected), and only BamHI data are indicated. Breakpoint junctions of MLL are indicated by numbers corresponding to known exons, and breakpoint junctions of ENL are given as letters presumed to be exon boundaries. G, unrearranged; R, rearranged; nd, not determined by RT-PCR sequence. (33) ]. In this way, cDNA extending from exon 5 of MLL to unknown sequence from the der(ll) chromosome was obtained (Fig. 2) . AF4 protein sequence was from cDNA made from RS411 cells ( Fig. 2A) and AFX1 was from K45 cDNA (Fig. 2B) . Both sequences indicate proteins rich in serineproline residues. This is similar to the situation with the ENL-derived protein (21) and raises the possibility that Ser-Pro-rich sequences are a common feature of the proteins joined to MLL in the acute leukemias with 11q23 abnormalities.
DISCUSSION
Rearrangements of MLL in Diverse Translocations. Cytogenetic analysis of acute leukemias has revealed a large number of translocations involving 11q23 in hematopoietic tumors of several phenotypes (17) . The MLL gene on chromosome 11, band q23, is involved in these translocations as judged by fluorescence in situ hybridization (25) , filter hybridization (20, 22, 24, 26, 27) , and gene cloning (18, 19, 21) . In the latter, it was shown that the translocations t(4;11) and t(11;19) break the MLL gene and genes on chromosomes 4 and 19, called AF4 and ENL, respectively (19, 21) . In this paper, rearrangement of MLL (taken to indicate position of a chromosomal translocation) is shown in eight different 11q23 translocations, not including t(4;11) and t (11;19) cases, and two deletions.
A combination of different restriction enzymes in hybridizations allowed the MLL rearrangements in the various tumors to be fairly precisely defined (19, 21 ) (see Table 1 and Fig. 1B (Table 1 ). There is a tendency for each of these three major translocations to be found in particular lineagesfor example, the t(9;11) is prevalent in ANLL-M5, whereas B-cell lineage tumors are mainly associated with the chromosome 4 and 19 partners. The precise position of the MLL rearrangement revealed no obvious correlation to cell type of the tumor. The group of ANLL t(9;11) cases has rearrangements between exon 4 and exon 9 with most clustered around exons 6-9, as do the predominantly pre-B-ALL tumors with t(4;11) (see Fig. 1C ). Using a RT-PCR-based procedure, we found involvement of MLL exon 7, although fusions of exons 6 and 8 also occur. No obvious distinction could be drawn between breakpoints in the infant, childhood, or adult t(4;11) tumors, and neither the MLL nor AF4 or ENL breakpoints entirely correlates with tumor phenotype. This fact is well illustrated for t (11;19) in which B-cell, T-cell, and nonlymphocytic lineages are afflicted by identical fusion points.
The data indicate that the various 11q23 chromosomal abnormalities occur in multipotent cells with the potential to differentiate along the various hematopoietic pathways. In most examples, the MLL fusion from the der(ll) chromosome will lack part, or all, of the zinc fingers. In addition, in some cases, deletions of the zinc fingers occur, suggesting that this loss, normally associated with der(ll), is the crucial consequence of the translocations. The mechanism of the deletions at 11q23 is unknown, but nonreciprocal translocations in acute leukemias are unusual (34) .
The previous sequence data on ENL (21) and the data presented here on AFXI and AF4 show that these genes encode proteins with Ser-Pro-rich regions. Clearly, examining different fusion proteins to establish the generality of this observation is important. It is nonetheless possible that the general consequence of 11q23 translocation in acute leukemias is attachment of a Ser-Pro-rich sequence at the COOH terminus of a truncated MLL. The der(ll) protein product may, therefore, have the DNA-binding A-T hook region of MLL attached to one of a series of related serine/proline sequences (possibly transcriptional activation domains), giving a protein that may bind DNA and interact with the transcriptional machinery to support gene activation.
Note Added In Proof. Complete sequences of AF4 and AF9 (35, 36) show that these genes encode Ser-Pro-rich proteins.
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